Form 4: Hologic Merger Completes, Ownership Changes Reported

Brandon Schnittker reports on changes in beneficial ownership of Hologic Inc. following a merger, detailing the conversion of stock options and units into cash and contingent value rights.

Summary

• This filing reports changes in beneficial ownership for Brandon Schnittker, President, GYN Surgical at Hologic Inc.
• The changes are a result of a merger between Hologic, Inc. and Hopper Parent Inc. (and its subsidiary Hopper Merger Sub Inc.).
• Hologic common stock was converted into $76.00 per share in cash plus one contingent value right (CVR) per share, potentially worth up to $3.00.
• Stock options with an exercise price below the cash consideration were converted into cash and a CVR.
• Stock options with an exercise price above the cash consideration but below the cash plus CVR value were converted into a CVR, with a net reduction based on the exercise price.
• Stock options with an exercise price above the cash plus CVR value were cancelled for no consideration.
• Restricted stock units (RSUs) converted into the right to receive the merger consideration (cash and CVR).
• Performance stock units (PSUs) had their performance goals deemed achieved at the greater of target or actual levels and were converted into the right to receive the merger consideration.
• As a result of the merger, the reporting person no longer beneficially owns any shares of Hologic common stock directly or indirectly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, as it confirms the completion of a merger that provides cash and potential upside to insiders and former shareholders, though some option holders with higher strike prices received no value.

Positives

• The merger provides shareholders with a cash payout of $76.00 per share, plus a potential additional $3.00 per share via a contingent value right (CVR).
• Stock options with exercise prices below the cash consideration were converted into a cash payment and a CVR, providing value to option holders.
• Performance stock units (PSUs) had their performance goals recognized, ensuring value realization for those units.

Negatives

• Stock options with exercise prices at or above $79.00 ($76.00 cash + $3.00 CVR) were cancelled with no consideration.
• The reporting person, Brandon Schnittker, no longer beneficially owns any shares of Hologic common stock directly or indirectly post-merger.

Risks

• The contingent value right (CVR) is not guaranteed and is dependent on the achievement of certain conditions, meaning the full $3.00 per share may not be realized.
• Options with higher exercise prices were cancelled, representing a loss of potential upside for those specific awards.

Future Outlook

The future outlook for Hologic as an independent entity is concluded due to the merger. The primary future financial event for former shareholders and option/unit holders is the potential payout of the contingent value rights (CVRs) up to $3.00 per share.

Management Comments

• The filing details the conversion of stock options and units into cash and contingent value rights as per the merger agreement.
• Performance goals for PSUs were deemed achieved at the greater of target or actual levels for conversion purposes.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects the completion of a significant M&A event for Hologic Inc., a company in the medical technology sector. Such filings are standard procedure to report changes in insider ownership following a change of control transaction, indicating the transition from public to private ownership or acquisition by another entity.

Stakeholder Impact

• Shareholders: Received $76.00 cash per share plus a CVR, representing a realization of their investment.
• Option Holders: Received cash and/or CVRs based on their option's strike price relative to the merger consideration.
• PSU Holders: Received merger consideration based on deemed achievement of performance goals.
• Employees: Those holding RSUs and PSUs received the merger consideration for their awards.

Next Steps

• Shareholders and former option/unit holders will await the determination and potential payout of the contingent value rights (CVRs).

Key Dates

Keywords

Hologic Inc, Merger, Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Performance Stock Units, Contingent Value Right, Brandon Schnittker, SEC Filing